Becton, Dickinson and Company (LON:0R19)
175.67
+0.33 (0.19%)
At close: Nov 7, 2025
LON:0R19 Revenue
In the fiscal year ending September 30, 2025, Becton, Dickinson and Company had annual revenue of $21.84B USD with 8.24% growth. Becton, Dickinson and Company had revenue of $5.89B in the quarter ending September 30, 2025, with 8.33% growth.
Revenue
$21.84B
Revenue Growth
+8.24%
P/S Ratio
2.38
Revenue / Employee
$312.00K
Employees
70,000
Market Cap
38.72B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 21.84B | 1.66B | 8.24% |
| Sep 30, 2024 | 20.18B | 806.00M | 4.16% |
| Sep 30, 2023 | 19.37B | 502.00M | 2.66% |
| Sep 30, 2022 | 18.87B | -261.00M | -1.36% |
| Sep 30, 2021 | 19.13B | 3.06B | 19.02% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| ConvaTec Group | 1.72B |
| Spire Healthcare Group | 1.55B |
| Genus | 672.80M |
Becton, Dickinson and Company News
- 1 day ago - Becton, Dickinson and Company 2025 Q4 - Results - Earnings Call Presentation - Seeking Alpha
- 1 day ago - Insider Sell: Bertram Scott Sells Shares of Becton Dickinson & Co (BDX) - GuruFocus
- 1 day ago - BDX: RBC Capital Lowers Price Target to $202, Maintains Rating | BDX Stock News - GuruFocus
- 2 days ago - Becton, Dickinson and Company: Strong Earnings But Murky Outlook - Seeking Alpha
- 2 days ago - Becton, Dickinson (BDX) Reports Strong Q4 and Sets Optimistic 2026 Guidance - GuruFocus
- 2 days ago - Becton Dickinson outlines $200M cost reduction and targets $14.75–$15.05 EPS for 2026 while expanding sales force - Seeking Alpha
- 2 days ago - Becton, Dickinson and Company (BDX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - 3 Undervalued Dividend Kings to Buy on the Dip Right Now - 24/7 Wall street